A complete 2026 guide to running compliant Google Ads campaigns for peptide brands. What Google flags, how to structure your account, and the ad-copy frameworks that scale without bans.
Quick answer: yes, you can run Google Ads for peptides, but only within the rules for your business type. Cosmetic and supplement peptide brands can advertise with compliant, structure/function claims. Research-use-only suppliers need consistent research-use positioning across ads, landing pages and checkout. Telehealth clinics need LegitScript and Google healthcare certification first. Compounds covered by Google's Unapproved Substances policy can't be promoted at all.
Start here: this article is part of our in-depth guides. For the full picture, read Peptide Marketing: The Complete Guide and Google Ads Healthcare and Medicines Policy Explained.
Advertising peptides on Google is one of the most technically demanding things you can do in paid media. The category sits at the intersection of regulated healthcare products, research chemicals, and aggressive platform policy — and Google updates its rules with very little warning.
Most peptide brands find out they’re doing it wrong only after their ads stop running.
This guide explains how to advertise peptides on Google without getting banned in 2026: what the policies actually say, where brands consistently go wrong, what compliant campaign architecture looks like, and the ad copy frameworks that convert without triggering flags.
Google classifies many peptides — BPC-157, TB-500, Ipamorelin, CJC-1295 — under healthcare and pharmaceutical advertising policies. The challenge is that the category is genuinely ambiguous. Research-grade peptides sold for laboratory use are not subject to FDA approval requirements for prescription drugs, but advertising them as if intended for human consumption creates immediate policy conflict.
Worth noting: Google's own Unapproved Substances policy text doesn't name "peptides" anywhere. Enforcement runs on function and marketing claims, not a fixed ingredient list — which is exactly why two brands selling the same compound can land on completely different sides of a policy decision depending on how they position it.
Before you touch ad copy, work out which of these three buckets your business actually falls into. Google reviews each one under a different policy section, with different certification requirements and different consequences for getting it wrong.
The enforcement isn't symmetrical across the three, either. Violations under the Healthcare and medicines policy tied to prescription-drug promotion can suspend an account "upon detection and without prior warning." That's a meaningfully harder failure mode than the Unapproved Substances policy, which — as covered next — builds in a warning window.
Consistently triggers flags: medical condition references, clinical outcome claims, pharmaceutical language (dosage, prescription, treatment protocol), before/after claims with specific metrics.
Generally passes: research-grade framing, athlete/biohacker audience language, quality/provenance signals, educational CTAs.
Not every disapproval carries the same risk. The Unapproved Substances policy — the one most peptide brands actually trip — includes a built-in safety net: a warning at least 7 days before suspension. We've written a full breakdown of how to monitor for that warning so you never miss it. Prescription-drug and telehealth violations under the Healthcare and medicines policy don't get that courtesy, which is exactly why Type 3 advertisers above need certification locked down before launch, not after a disapproval. If you're already suspended, read our Google Ads suspension appeal guide first.
Two more keyword-level risk factors worth calling out directly: putting compound names — BPC-157, TB-500, CJC-1295, Ipamorelin, Melanotan — into your actual keyword list (rather than just your ad copy) tends to trigger automated review on its own, and a mismatch between research-use ad copy and a consumer-wellness audience or landing page is one of the fastest ways to get flagged even when the copy itself reads as compliant.
In April 2026, the FDA removed 12 peptides from its Category 2 "do not compound" bulk substances list: BPC-157, Thymosin Beta-4 Fragment (TB-500), GHK-Cu (injectable routes), Melanotan II, Semax, Epitalon, KPV, MOTs-C, Dihexa Acetate, Cathelicidin LL-37, PEG-MGF, and DSIP.
Some brands are reading this as a green light for looser marketing. It isn't. Removal from Category 2 means these substances are no longer on the FDA's explicit "cannot compound under any circumstances" list — it does not mean they're approved drugs, and it doesn't establish that a compounding pharmacy can legally prepare them for human use. That depends on separate FDA enforcement-discretion decisions and a formal rulemaking process that hadn't concluded as of this writing. For Google Ads purposes, none of this changes your exposure under the Unapproved Substances or Healthcare and medicines policies — Google enforces based on your ad claims and landing page, not on where a compound currently sits in FDA's compounding categories. Don't let this update talk you into looser ad copy.
Brand Search (launch first) → Non-Brand High-Intent → Non-Brand Educational → Google Shopping → Display Remarketing. Comprehensive negative keyword lists from day one — both performance and compliance reasons.
See this architecture in action — a peptide brand scaled from $8K to $148K/month.
The framework: position around the audience and credibility, not medical claims. For supplement and skincare advertisers specifically, the legal anchor for this is DSHEA's structure/function standard — you can describe what a product supports in the body, never what it treats, prevents, or cures. That distinction is the difference between an approved ad and a disapproved one, almost word for word.
If you're in the telehealth bucket (Type 3 above), the same principle applies to service ads, not just product ads: sell the consultation, not the compound. "Online peptide therapy consultations with licensed providers" clears review; naming a specific compound or dosage in the same headline generally doesn't — even once you're fully certified.
Google’s review system follows your URL. “For research use only” statement visible above the fold. No before/after testimonials with health claims. COA visible. No language implying FDA approval.
Weekly ad review, policy change monitoring, 24-hour disapproval response, clean bidding transitions. Here’s one example of this working — $0 to $260K in 6 months.
Can I advertise peptides on Google Ads at all?
Yes — but what's allowed depends on which of the three advertiser types above you are. Skincare and supplement brands can run standard campaigns with compliant claims; research peptide companies can advertise with strict research-use positioning; telehealth clinics need LegitScript certification plus Google's own healthcare certification before ads run.
Do I need LegitScript certification to advertise peptides?
Only if you're a telehealth or prescribing service. Skincare and supplement brands don't need it as long as claims stay compliant, and research peptide companies aren't required to hold it either, though they still have to maintain strict research-use-only positioning throughout.
Why do peptide Google Ads keep getting disapproved?
The most common causes are health claims in the copy, dosage information on the landing page, compound names used as keywords, a mismatch between research-use copy and a consumer-facing audience, and slow responses to earlier disapprovals — Google treats an unaddressed disapproval as a signal the account isn't trying to comply.
Does the 2026 FDA peptide update change what I can advertise?
No. The April 2026 removal of 12 peptides from FDA's Category 2 compounding list didn't approve them for human use, and it has no bearing on Google's own ad policies, which judge your ads and landing pages on their own terms regardless of a compound's compounding-list status.
Working with a compliant paid media agency that understands the peptide space makes the difference between sustainable growth and a banned account. Get a free strategy session with Oney Studio.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit